APO Research
Talk to an analyst

APO RESEARCH · REPORT

Giant Cell Arteritis Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Giant Cell Arteritis Therapeutic Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchGiant Cell Arteritis Therapeutic Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Giant Cell Arteritis Therapeutic Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Giant Cell Arteritis Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Giant Cell Arteritis Therapeutic Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Giant Cell Arteritis Therapeutic Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Giant Cell Arteritis Therapeutic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Giant Cell Arteritis Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Giant Cell Arteritis Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Giant Cell Arteritis Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Giant Cell Arteritis Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Giant Cell Arteritis Therapeutic include Abbott, Sanofi, Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline plc, AbbVie, Inc., Regeneron, Lahey Clinic Foundation and Kiniksa Pharmaceuticals, Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Giant Cell Arteritis Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Giant Cell Arteritis Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for Giant Cell Arteritis Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Giant Cell Arteritis Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Giant Cell Arteritis Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Giant Cell Arteritis Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Giant Cell Arteritis Therapeutic Segment by Company

Abbott

Sanofi

Johnson & Johnson Services, Inc.

Novartis AG

GlaxoSmithKline plc

AbbVie, Inc.

Regeneron

Lahey Clinic Foundation

Kiniksa Pharmaceuticals, Ltd.

Johns Hopkins Hospital

Fortis Healthcare

F. Hoffmann-La Roche Ltd.

Duke University Health System

Bristol-Myers Squibb Company

American College of Rheumatology

Giant Cell Arteritis Therapeutic Segment by Type

Tocilizumab

Prednisone

Methotrexate

Aspirin

Giant Cell Arteritis Therapeutic Segment by Application

Anticoagulants

Immunosuppressive Agents

Corticosteroids

Others

Giant Cell Arteritis Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Giant Cell Arteritis Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Giant Cell Arteritis Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Giant Cell Arteritis Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Giant Cell Arteritis Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Giant Cell Arteritis Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Giant Cell Arteritis Therapeutic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Giant Cell Arteritis Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tocilizumab Major Player Table 3. Prednisone Major Player Table 4. Methotrexate Major Player Table 5. Aspirin Major Player Table 6. Global Giant Cell Arteritis Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Anticoagulants Major Player Table 8. Immunosuppressive Agents Major Player Table 9. Corticosteroids Major Player Table 10. Others Major Player Table 11. Giant Cell Arteritis Therapeutic Industry Trends Table 12. Giant Cell Arteritis Therapeutic Industry Drivers Table 13. Giant Cell Arteritis Therapeutic Industry Opportunities and Challenges Table 14. Giant Cell Arteritis Therapeutic Industry Restraints Table 15. Global Giant Cell Arteritis Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Giant Cell Arteritis Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Giant Cell Arteritis Therapeutic Market Share by Region (2021-2026) Table 18. Global Giant Cell Arteritis Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Giant Cell Arteritis Therapeutic Market Share by Region (2027-2032) Table 20. Global Giant Cell Arteritis Therapeutic Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Players (2021-2026) Table 22. Global Giant Cell Arteritis Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Giant Cell Arteritis Therapeutic Key Players Headquarters & Area Served Table 24. Global Giant Cell Arteritis Therapeutic Players, Product Type & Application Table 25. Global Giant Cell Arteritis Therapeutic Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Giant Cell Arteritis Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Giant Cell Arteritis Therapeutic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Type (2021-2026) Table 32. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Type (2027-2032) Table 33. Global Giant Cell Arteritis Therapeutic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Application (2021-2026) Table 37. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Application (2027-2032) Table 38. Abbott Company Information Table 39. Abbott Business Overview Table 40. Abbott Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Abbott Giant Cell Arteritis Therapeutic Product Portfolio Table 42. Abbott Recent Development Table 43. Sanofi Company Information Table 44. Sanofi Business Overview Table 45. Sanofi Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Sanofi Giant Cell Arteritis Therapeutic Product Portfolio Table 47. Sanofi Recent Development Table 48. Johnson & Johnson Services, Inc. Company Information Table 49. Johnson & Johnson Services, Inc. Business Overview Table 50. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product Portfolio Table 52. Johnson & Johnson Services, Inc. Recent Development Table 53. Novartis AG Company Information Table 54. Novartis AG Business Overview Table 55. Novartis AG Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Novartis AG Giant Cell Arteritis Therapeutic Product Portfolio Table 57. Novartis AG Recent Development Table 58. GlaxoSmithKline plc Company Information Table 59. GlaxoSmithKline plc Business Overview Table 60. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product Portfolio Table 62. GlaxoSmithKline plc Recent Development Table 63. AbbVie, Inc. Company Information Table 64. AbbVie, Inc. Business Overview Table 65. AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. AbbVie, Inc. Giant Cell Arteritis Therapeutic Product Portfolio Table 67. AbbVie, Inc. Recent Development Table 68. Regeneron Company Information Table 69. Regeneron Business Overview Table 70. Regeneron Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Regeneron Giant Cell Arteritis Therapeutic Product Portfolio Table 72. Regeneron Recent Development Table 73. Lahey Clinic Foundation Company Information Table 74. Lahey Clinic Foundation Business Overview Table 75. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product Portfolio Table 77. Lahey Clinic Foundation Recent Development Table 78. Kiniksa Pharmaceuticals, Ltd. Company Information Table 79. Kiniksa Pharmaceuticals, Ltd. Business Overview Table 80. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product Portfolio Table 82. Kiniksa Pharmaceuticals, Ltd. Recent Development Table 83. Johns Hopkins Hospital Company Information Table 84. Johns Hopkins Hospital Business Overview Table 85. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product Portfolio Table 87. Johns Hopkins Hospital Recent Development Table 88. Fortis Healthcare Company Information Table 89. Fortis Healthcare Business Overview Table 90. Fortis Healthcare Giant Cell Arteritis Therapeutic Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Fortis Healthcare Giant Cell Arteritis Therapeutic Product Portfolio Table 92. Fortis Healthcare Recent Development Table 93. F. Hoffmann-La Roche Ltd. Company Information Table 94. F. Hoffmann-La Roche Ltd. Business Overview Table 95. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product Portfolio Table 97. F. Hoffmann-La Roche Ltd. Recent Development Table 98. Duke University Health System Company Information Table 99. Duke University Health System Business Overview Table 100. Duke University Health System Giant Cell Arteritis Therapeutic Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Duke University Health System Giant Cell Arteritis Therapeutic Product Portfolio Table 102. Duke University Health System Recent Development Table 103. Bristol-Myers Squibb Company Company Information Table 104. Bristol-Myers Squibb Company Business Overview Table 105. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product Portfolio Table 107. Bristol-Myers Squibb Company Recent Development Table 108. American College of Rheumatology Company Information Table 109. American College of Rheumatology Business Overview Table 110. American College of Rheumatology Giant Cell Arteritis Therapeutic Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. American College of Rheumatology Giant Cell Arteritis Therapeutic Product Portfolio Table 112. American College of Rheumatology Recent Development Table 113. North America Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 119. North America Giant Cell Arteritis Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 120. Europe Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 123. Europe Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 124. Europe Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Europe Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Giant Cell Arteritis Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 127. China Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 128. China Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 129. China Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 130. China Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 132. Asia Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 133. Asia Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 134. Asia Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Giant Cell Arteritis Therapeutic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Asia Giant Cell Arteritis Therapeutic Revenue by Region (US$ Million) & (2021-2026) Table 137. Asia Giant Cell Arteritis Therapeutic Revenue by Region (US$ Million) & (2027-2032) Table 138. SAMEA Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 139. SAMEA Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 140. SAMEA Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 141. SAMEA Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 142. SAMEA Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. SAMEA Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 144. SAMEA Giant Cell Arteritis Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Giant Cell Arteritis Therapeutic Image Figure 2. Global Giant Cell Arteritis Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Giant Cell Arteritis Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tocilizumab Image Figure 5. Prednisone Image Figure 6. Methotrexate Image Figure 7. Aspirin Image Figure 8. Global Giant Cell Arteritis Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Giant Cell Arteritis Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 10. Anticoagulants Image Figure 11. Immunosuppressive Agents Image Figure 12. Corticosteroids Image Figure 13. Others Image Figure 14. Global Giant Cell Arteritis Therapeutic Market Size (US$ Million) & (2021-2032) Figure 15. Global Giant Cell Arteritis Therapeutic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Giant Cell Arteritis Therapeutic Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Giant Cell Arteritis Therapeutic Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Giant Cell Arteritis Therapeutic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Giant Cell Arteritis Therapeutic Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Type (2021-2032) Figure 22. Global Giant Cell Arteritis Therapeutic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Giant Cell Arteritis Therapeutic Revenue Market Share by Application (2021-2032) Figure 25. North America Giant Cell Arteritis Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032) Figure 27. North America Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032) Figure 28. North America Giant Cell Arteritis Therapeutic Revenue Share by Country (2021-2032) Figure 29. United States Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Giant Cell Arteritis Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032) Figure 34. Europe Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032) Figure 35. Europe Giant Cell Arteritis Therapeutic Revenue Share by Country (2021-2032) Figure 36. Germany Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Giant Cell Arteritis Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032) Figure 46. China Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032) Figure 47. Asia Giant Cell Arteritis Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032) Figure 49. Asia Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032) Figure 50. Asia Giant Cell Arteritis Therapeutic Revenue Share by Region (2021-2032) Figure 51. Japan Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Giant Cell Arteritis Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032) Figure 59. SAMEA Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032) Figure 60. SAMEA Giant Cell Arteritis Therapeutic Revenue Share by Country (2021-2032) Figure 61. Brazil Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Giant Cell Arteritis Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Tocilizumab
  • Prednisone
  • Methotrexate
  • Aspirin
Applications
  • Anticoagulants
  • Immunosuppressive Agents
  • Corticosteroids
  • Others
Companies covered
  • Abbott
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • AbbVie, Inc.
  • Regeneron
  • Lahey Clinic Foundation
  • Kiniksa Pharmaceuticals, Ltd.
  • Johns Hopkins Hospital
  • Fortis Healthcare
  • F. Hoffmann-La Roche Ltd.
  • Duke University Health System
  • Bristol-Myers Squibb Company
  • American College of Rheumatology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Giant Cell Arteritis Therapeutic Market by Type
  3. 1.2.1 Global Giant Cell Arteritis Therapeutic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tocilizumab
  5. 1.2.3 Prednisone
  6. 1.2.4 Methotrexate
  7. 1.2.5 Aspirin
  8. 1.3 Giant Cell Arteritis Therapeutic Market by Application
  9. 1.3.1 Global Giant Cell Arteritis Therapeutic Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Anticoagulants
  11. 1.3.3 Immunosuppressive Agents
  12. 1.3.4 Corticosteroids
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Giant Cell Arteritis Therapeutic Market Dynamics
  1. 2.1 Giant Cell Arteritis Therapeutic Industry Trends
  2. 2.2 Giant Cell Arteritis Therapeutic Industry Drivers
  3. 2.3 Giant Cell Arteritis Therapeutic Industry Opportunities and Challenges
  4. 2.4 Giant Cell Arteritis Therapeutic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Giant Cell Arteritis Therapeutic Market Perspective (2021-2032)
  2. 3.2 Global Giant Cell Arteritis Therapeutic Growth Trends by Region
  3. 3.2.1 Global Giant Cell Arteritis Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Giant Cell Arteritis Therapeutic Market Size by Region (2021-2026)
  5. 3.2.3 Global Giant Cell Arteritis Therapeutic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Giant Cell Arteritis Therapeutic Revenue by Players
  2. 4.1.1 Global Giant Cell Arteritis Therapeutic Revenue by Players (2021-2026)
  3. 4.1.2 Global Giant Cell Arteritis Therapeutic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Giant Cell Arteritis Therapeutic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Giant Cell Arteritis Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Giant Cell Arteritis Therapeutic Key Players Headquarters & Area Served
  7. 4.4 Global Giant Cell Arteritis Therapeutic Players, Product Type & Application
  8. 4.5 Global Giant Cell Arteritis Therapeutic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Giant Cell Arteritis Therapeutic Market CR5 and HHI
  11. 4.6.3 2025 Giant Cell Arteritis Therapeutic Tier 1, Tier 2, and Tier 3
5 Giant Cell Arteritis Therapeutic Market Size by Type
  1. 5.1 Global Giant Cell Arteritis Therapeutic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Giant Cell Arteritis Therapeutic Revenue by Type (2021-2032)
  3. 5.3 Global Giant Cell Arteritis Therapeutic Revenue Market Share by Type (2021-2032)
6 Giant Cell Arteritis Therapeutic Market Size by Application
  1. 6.1 Global Giant Cell Arteritis Therapeutic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Giant Cell Arteritis Therapeutic Revenue by Application (2021-2032)
  3. 6.3 Global Giant Cell Arteritis Therapeutic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Giant Cell Arteritis Therapeutic Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Giant Cell Arteritis Therapeutic Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Johnson & Johnson Services, Inc.
  14. 7.3.1 Johnson & Johnson Services, Inc. Company Information
  15. 7.3.2 Johnson & Johnson Services, Inc. Business Overview
  16. 7.3.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product Portfolio
  18. 7.3.5 Johnson & Johnson Services, Inc. Recent Developments
  19. 7.4 Novartis AG
  20. 7.4.1 Novartis AG Company Information
  21. 7.4.2 Novartis AG Business Overview
  22. 7.4.3 Novartis AG Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis AG Giant Cell Arteritis Therapeutic Product Portfolio
  24. 7.4.5 Novartis AG Recent Developments
  25. 7.5 GlaxoSmithKline plc
  26. 7.5.1 GlaxoSmithKline plc Company Information
  27. 7.5.2 GlaxoSmithKline plc Business Overview
  28. 7.5.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product Portfolio
  30. 7.5.5 GlaxoSmithKline plc Recent Developments
  31. 7.6 AbbVie, Inc.
  32. 7.6.1 AbbVie, Inc. Company Information
  33. 7.6.2 AbbVie, Inc. Business Overview
  34. 7.6.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product Portfolio
  36. 7.6.5 AbbVie, Inc. Recent Developments
  37. 7.7 Regeneron
  38. 7.7.1 Regeneron Company Information
  39. 7.7.2 Regeneron Business Overview
  40. 7.7.3 Regeneron Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Regeneron Giant Cell Arteritis Therapeutic Product Portfolio
  42. 7.7.5 Regeneron Recent Developments
  43. 7.8 Lahey Clinic Foundation
  44. 7.8.1 Lahey Clinic Foundation Company Information
  45. 7.8.2 Lahey Clinic Foundation Business Overview
  46. 7.8.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product Portfolio
  48. 7.8.5 Lahey Clinic Foundation Recent Developments
  49. 7.9 Kiniksa Pharmaceuticals, Ltd.
  50. 7.9.1 Kiniksa Pharmaceuticals, Ltd. Company Information
  51. 7.9.2 Kiniksa Pharmaceuticals, Ltd. Business Overview
  52. 7.9.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product Portfolio
  54. 7.9.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments
  55. 7.10 Johns Hopkins Hospital
  56. 7.10.1 Johns Hopkins Hospital Company Information
  57. 7.10.2 Johns Hopkins Hospital Business Overview
  58. 7.10.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product Portfolio
  60. 7.10.5 Johns Hopkins Hospital Recent Developments
  61. 7.11 Fortis Healthcare
  62. 7.11.1 Fortis Healthcare Company Information
  63. 7.11.2 Fortis Healthcare Business Overview
  64. 7.11.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Product Portfolio
  66. 7.11.5 Fortis Healthcare Recent Developments
  67. 7.12 F. Hoffmann-La Roche Ltd.
  68. 7.12.1 F. Hoffmann-La Roche Ltd. Company Information
  69. 7.12.2 F. Hoffmann-La Roche Ltd. Business Overview
  70. 7.12.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  71. 7.12.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product Portfolio
  72. 7.12.5 F. Hoffmann-La Roche Ltd. Recent Developments
  73. 7.13 Duke University Health System
  74. 7.13.1 Duke University Health System Company Information
  75. 7.13.2 Duke University Health System Business Overview
  76. 7.13.3 Duke University Health System Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Duke University Health System Giant Cell Arteritis Therapeutic Product Portfolio
  78. 7.13.5 Duke University Health System Recent Developments
  79. 7.14 Bristol-Myers Squibb Company
  80. 7.14.1 Bristol-Myers Squibb Company Company Information
  81. 7.14.2 Bristol-Myers Squibb Company Business Overview
  82. 7.14.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product Portfolio
  84. 7.14.5 Bristol-Myers Squibb Company Recent Developments
  85. 7.15 American College of Rheumatology
  86. 7.15.1 American College of Rheumatology Company Information
  87. 7.15.2 American College of Rheumatology Business Overview
  88. 7.15.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue and Gross Margin (2021-2026)
  89. 7.15.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Product Portfolio
  90. 7.15.5 American College of Rheumatology Recent Developments
8 North America
  1. 8.1 North America Giant Cell Arteritis Therapeutic Revenue (2021-2032)
  2. 8.2 North America Giant Cell Arteritis Therapeutic Revenue by Type (2021-2032)
  3. 8.2.1 North America Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026)
  4. 8.2.2 North America Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032)
  5. 8.3 North America Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032)
  6. 8.4 North America Giant Cell Arteritis Therapeutic Revenue by Application (2021-2032)
  7. 8.4.1 North America Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026)
  8. 8.4.2 North America Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032)
  9. 8.5 North America Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032)
  10. 8.6 North America Giant Cell Arteritis Therapeutic Revenue by Country
  11. 8.6.1 North America Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026)
  13. 8.6.3 North America Giant Cell Arteritis Therapeutic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Giant Cell Arteritis Therapeutic Revenue (2021-2032)
  2. 9.2 Europe Giant Cell Arteritis Therapeutic Revenue by Type (2021-2032)
  3. 9.2.1 Europe Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026)
  4. 9.2.2 Europe Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032)
  5. 9.3 Europe Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032)
  6. 9.4 Europe Giant Cell Arteritis Therapeutic Revenue by Application (2021-2032)
  7. 9.4.1 Europe Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026)
  8. 9.4.2 Europe Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032)
  9. 9.5 Europe Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032)
  10. 9.6 Europe Giant Cell Arteritis Therapeutic Revenue by Country
  11. 9.6.1 Europe Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026)
  13. 9.6.3 Europe Giant Cell Arteritis Therapeutic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Giant Cell Arteritis Therapeutic Revenue (2021-2032)
  2. 10.2 China Giant Cell Arteritis Therapeutic Revenue by Type (2021-2032)
  3. 10.2.1 China Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026)
  4. 10.2.2 China Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032)
  5. 10.3 China Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032)
  6. 10.4 China Giant Cell Arteritis Therapeutic Revenue by Application (2021-2032)
  7. 10.4.1 China Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026)
  8. 10.4.2 China Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032)
  9. 10.5 China Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Giant Cell Arteritis Therapeutic Revenue (2021-2032)
  2. 11.2 Asia Giant Cell Arteritis Therapeutic Revenue by Type (2021-2032)
  3. 11.2.1 Asia Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026)
  4. 11.2.2 Asia Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032)
  5. 11.3 Asia Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032)
  6. 11.4 Asia Giant Cell Arteritis Therapeutic Revenue by Application (2021-2032)
  7. 11.4.1 Asia Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026)
  8. 11.4.2 Asia Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032)
  9. 11.5 Asia Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032)
  10. 11.6 Asia Giant Cell Arteritis Therapeutic Revenue by Country
  11. 11.6.1 Asia Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026)
  13. 11.6.3 Asia Giant Cell Arteritis Therapeutic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Giant Cell Arteritis Therapeutic Revenue (2021-2032)
  2. 12.2 SAMEA Giant Cell Arteritis Therapeutic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Giant Cell Arteritis Therapeutic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Giant Cell Arteritis Therapeutic Revenue by Type (2027-2032)
  5. 12.3 SAMEA Giant Cell Arteritis Therapeutic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Giant Cell Arteritis Therapeutic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Giant Cell Arteritis Therapeutic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Giant Cell Arteritis Therapeutic Revenue by Application (2027-2032)
  9. 12.5 SAMEA Giant Cell Arteritis Therapeutic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Giant Cell Arteritis Therapeutic Revenue by Country
  11. 12.6.1 SAMEA Giant Cell Arteritis Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Giant Cell Arteritis Therapeutic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Giant Cell Arteritis Therapeutic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst